Valuation • Polaryx Therapeutics
PLYX
Polaryx Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for lysosomal storage disorders (LSDs) and other rare, life-threatening diseases. The company's primary focus is on repurposing and optimizing existing compounds to address the unmet medical needs of patients with genetic disorders that affect the central nervous system and other vital organs. Polaryx's lead product candidate, PLX-101, is an oral small molecule being developed for the treatment of Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL), also known as CLN2 disease. PLX-101 works by activating the Peroxisome Proliferator-Activated Receptor alpha (PPARα) and the Transcription Factor EB (TFEB), which are critical regulators of lysosomal biogenesis and autophagy. By enhancing these pathways, the therapy aims to reduce the accumulation of toxic storage material in cells, potentially slowing or halting disease progression. In addition to CLN2, the company is exploring the application of its technology platform across other forms of Neuronal Ceroid Lipofuscinosis (NCL) and various lysosomal storage diseases. Polaryx leverages a strategy of utilizing well-characterized molecules to accelerate clinical development timelines and reduce safety risks. The company is led by a management team with extensive experience in drug development and rare disease research, aiming to provide accessible, non-invasive treatment options for pediatric and adult patients worldwide.
43
P/B
Book value of equity per share effectively indicates a firm's net asset value (total assets - total liabilities) on a per-share basis. References: Below 1: the company is trading below its equity. Equal to 1: the company is trading at the exact value of its equity. Above 1: The company is trading above its equity.
—
P/S
Shows how much the market values every dollar of the company's sales.
—
P/EBITDA
Shows how much the market values every dollar of the company's EBITDA.
—
P/OCF
The price-to-cash flow (P/CF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its operating cash flow per share. The ratio uses operating cash flow (OCF), which adds back non-cash expenses such as depreciation and amortization to net income. P/CF is especially useful for valuing stocks that have positive cash flow but are not profitable because of large non-cash charges.
—
P/FCF
The price-to-free cash flow (P/FCF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its free cash flow per share. This metric is very similar to the valuation metric of price to cash flow but is considered a more exact measure because it uses free cash flow, which subtracts capital expenditures (CAPEX) from a company's total operating cash flow, thereby reflecting the actual cash flow available to fund non-asset-related growth.
—
P/E
The price-to-earnings ratio is the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS) and is used by investors and analysts to determine the relative value of a company's shares in an apples-to-apples comparison.
0,1
BVPS
Book value per share (BVPS) takes the ratio of a firm's common equity divided by its number of shares outstanding.
—
EPS
Earnings per share (EPS) is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability. EPS indicates how much money a company makes for each share of its stock and is a widely used metric for estimating corporate value.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!